TAMPA, FL, February 21, 2023 – EV Biologics Corp (OTC PINK:YECO), announced that it has successfully generated several mesenchymal stem/stromal cell (MSC) lines for secretome production and further cell line development. The cell banks were isolated from rigorously screened human donor tissue using xeno-free, serum-free culture media for isolation and expansion, after obtaining informed consent (from donors) for research and development. Analysis of the cell lines confirmed their identity as MSCs according to established criteria.
The Company will use these cell banks for production of their secretome, containing extracellular vesicles, including exosomes, as well as other bioactive proteins and RNA. MSC secretome products have demonstrated great potential for a broad range of therapeutic applications, with the greatest benefits having been demonstrated using young stem cells such as these.
The gene expression of these cell banks will be further analyzed to identify optimal cell subpopulations for further cell line development. Their secretome products will be analyzed using multi-omics and cell-based assays to identify the bioactive constituents of their composition and to correlate their bioactivity with specific subpopulations.
CEO, Daniel Mckinney, said, “This is exciting news. Creation of this cell bank has been our main priority since 2020 and now we have achieved the goal. MSC lines are the foundation for our therapeutic development initiatives. Further analysis of these cell banks and their secretomes will yield continued cell line development and therapeutic product optimization for our specific clinical indications.”
About EV Biologics
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, developing a range of nanotherapeutics to substantially enhance the intrinsic bioactivity of stem and progenitor cell-derived nanoparticles. The Company is also developing biomanufacturing, bioinformatic and bioengineering innovations to optimize production of nanoparticle therapeutics and biologics. These versatile therapeutic platforms will enable generation of nanotherapeutics targeting a broad range of regenerative medicine and longevity applications.
About Excyte
Excyte, a wholly owned subsidiary of EV Biologics, Inc., is founded on the idea that potent biotherapeutics and a deeper understanding of health, disease and aging can be obtained from living cells. Our mission is to further the understanding of the complex interactions between the multiplex of functional biomolecules that comprise cell-derived nanotherapeutics and the interconnected cellular pathways of biological systems in disease and aging. The Company is focused on innovation in biomanufacturing, bioengineering, bio analytics and machine learning in support of a versatile platform for on-demand precision nanotherapeutic development for any clinical indication. Our innovative approach to longevity will use a multi-functional nanotherapeutic platform to deliver the right bioactive molecules to diseased, damaged or aging cells to restore health, combat aging and provide a longer health span.
To learn more about this rapidly expanding market, view the “The Global Exosome Market – Market Size, Forecast, Trials and Trends.”
